Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report

Phenylbutyric Acid: Simple Structure - Multiple Effects

(2015) Magdalena Kusaczuk et al.   CURRENT PHARMACEUTICAL DESIGN

Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway

(2015) Tieyi Hu et al.   TUMOR BIOLOGY

Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line

(2015) Magdalena Kusaczuk et al.   TUMOR BIOLOGY

Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat

(2015) Soumen Kahali et al.   NEOPLASIA

Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe

(2014) M Cornago et al.   Cell Death & Disease

Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells

(2014) Akinori Sato et al.   BMC Urology

Molecular Chaperone ORP150 in ER Stress–related Diseases

(2013) Magdalena Kusaczuk et al.   CURRENT PHARMACEUTICAL DESIGN

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

(2013) Daniel Chan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

(2013) Wenwen Chien et al.   MOLECULAR CARCINOGENESIS

Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

(2013) Shu-Fu Lin et al.   PLoS One

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

(2012) Dmitriy I Dovzhanskiy et al.   BMC CANCER

Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response

(2012) Soumen Kahali et al.   FASEB JOURNAL

1H NMR Metabolomics Analysis of Glioblastoma Subtypes

(2012) Miroslava Cuperlovic-Culf et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

(2012) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

(2011) Amanda Cashen et al.   ANNALS OF HEMATOLOGY

Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells

(2011) Feng-Ming Wang et al.   EXPERIMENTAL HEMATOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Nonhistone protein acetylation as cancer therapy targets

(2010) Brahma N Singh et al.   Expert Review of Anticancer Therapy

Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

(2010) Rekha Rao et al.   MOLECULAR CANCER THERAPEUTICS

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

(2009) Anne Monks et al.   ANTI-CANCER DRUGS

Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin

(2009) KetLi Ho et al.   Cancer Epidemiology

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

(2009) Peter Gimsing   EXPERT OPINION ON INVESTIGATIONAL DRUGS

High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray

(2009) D. Yin et al.   MOLECULAR CANCER RESEARCH

Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis

(2009) P. Baumeister et al.   MOLECULAR CANCER THERAPEUTICS

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay

(2008) Jin C. Kim et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis

(2008) Hae Kyung Lee et al.   NEURO-ONCOLOGY